To stimulate the development of new drugs for the cognitive deficits of schizophrenia,
the National Institute of Mental Health (NIMH) established the Measurement and Treatment
Research to Improve Cognition in Schizophrenia (MATRICS) initiative. This article
presents an overview of decisions from the first MATRICS consensus conference. The
goals of the meeting were to 1) identify the cognitive domains that should be represented
in a consensus cognitive battery and 2) prioritize key criteria for selection of tests
for the battery. Seven cognitive domains were selected based on a review of the literature
and input from experts: working memory, attention/vigilance, verbal learning and memory,
visual learning and memory, reasoning and problem solving, speed of processing, and
social cognition. Based on discussions at this meeting, five criteria were considered
essential for test selection: good test–retest reliability, high utility as a repeated
measure, relationship to functional outcome, potential response to pharmacologic agents,
and practicality/tolerability. The results from this meeting constitute the initial
steps for reaching a consensus cognitive battery for clinical trials in schizophrenia.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neurocognitive impairments in non-psychotic parents of children with schizophrenia and attention deficit hyperactivity disorder.Arch Gen Psychiatry. 2002; 59: 1053-1060
- Evaluation of social problem solving in schizophrenia.J Abnorm Psychol. 1994; 103: 371-378
- Neuropsychology of first-episode schizophrenia.Am J Psychiatry. 2000; 157: 549-559
- Cognitive effects of typical antipsychotic treatment: Another look.in: Sharma T. Harvey P.D. Cognition in Schizophrenia. Oxford University Press, . New York2000: 241-265
- Information processing and attention dysfunctions in schizophrenia.Schizophr Bull. 1993; 9: 233-259
- The neural basis of primate social communication.Motivation Emotion. 1990; 14: 81-91
- Initial and final work performance in schizophrenia.J Nerv Ment Dis. 2003; 91: 87-92
- Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers.Arch Gen Psychiatry. 1994; 51: 651-661
- Another view of therapy for cognition in schizophrenia.Biol Psychiatry. 2002; 51: 969-971
- Neuroleptics.Schizophr Bull. 1990; 6: 477-499
- Reversal of antipsychotic-induced working memory deficits by short-terms dopamine D1 receptor stimulation.Science. 2000; 287: 2020-2022
- Childhood attentional dysfunction predicts social deficits in unaffected adults at risk for schizophrenia.Br J Psychiatry. 1992; 161: 59-64
- Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents.Am J Psychiatry. 1999; 156: 1328-1335
- Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.J Abnorm Psychol. 1997; 106: 203-212
- The RAND/UCLA Appropriateness Users Manual.RAND Institute, Santa Monica2001
- Reaction time measures of sustained attention differentiate bipolar disorder from schizophrenia.Schizophr Res. 2001; 52: 251-259
- Neurocognition and community outcome in schizophrenia.Schizophr Res. 2003; 59: 219-223
- D-cycloserine added to clozapine for patients with schizophrenia.Am J Psychiatry. 1996; 153: 1628-1630
- Cognitive correlates of job tenure among patients with severe mental illness.Am J Psychiatry. 2002; 159: 1395-1401
Gold JM, Green MF (in press): Neurocognition in schizophrenia. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 8th ed. Baltimore: Lippincott, Williams & Wilkins.
- Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery.Am J Psychiatry. 1993; 150: 1355-1362
- Neurocognitive functioning in patients with schizophrenia.in: Davis K.L. Charney D. Coyle J.T. Nemeroff C. Neuropsychopharmacology: The Fifth Generation of Progress. Williams & Wilkins, Philadelphia: Lippincott2002
- Neuropsychological assessment of monozygotic twins discordant for schizophrenia.Arch Gen Psychiatry. 1990; 47: 1066-1072
- What are the functional consequences of neurocognitive deficits in schizophrenia?.Am J Psychiatry. 1996; 153: 321-330
- Neurocognitive deficits and functional outcome in schizophrenia.Schizophr Bull. 2000; 26: 119-136
- The neurocognitive effects of low-dose haloperidol.Biol Psychiatry. 2002; 51: 972-978
- Should schizophrenia be treated as a neurocognitive disorder?.Schizophr Bull. 1999; 25: 309-319
- Backward masking performance in unaffected siblings of schizophrenia patients.Arch Gen Psychiatry. 1997; 54: 465-472
- Modulating emotional responses.Neuro Report. 2000; 11: 43-48
- Studies of the cognitive change in patients with schizophrenia following novel antipsychotic treatment.Am J Psychiatry. 2001; 158: 176-184
- What are the right targets for psychopharmacology?.Science. 2003; 299: 350-351
- The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia.Schizophr Bull. 1999; 25: 201-222
- To increase power without increasing sample size.Psychopharmacol Bull. 1991; 27: 217-224
- Neuropsychological Assessment.3rd ed. Oxford University Press, New York1995
- Opposing roles of dopamine and serotonin in the modulation of human spatial working memory functions.Cereb Cortex. 1998; 8: 218-226
- The Copenhagen high-risk project, 1962-86.Schizophr Bull. 1987; 13: 485-495
- The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr Bull. 1999; 25: 233-255
- Generalized cognitive deficits in schizophrenia.Am J Psychiatry. 1999; 156: 749-754
- Symptoms and cognition as predictors of community functioning.Am J Psychiatry. 1999; 156: 400-405
- Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children.J Abnorm Psychol. 1983; 92: 4-28
- Neurocognitive vulnerability factors for schizophrenia: Convergence across genetic risk studies and longitudinal trait/state studies.in: Lenzenweger M.F. Dworkin R.H. Origins and Development of Schizophrenia: Advances in Experimental Psychopathology. American Psychological Association, Washington, DC1998: 299-327
- Information processing and attentional functioning in the developmental course of schizophrenia disorders.Schizophr Bull. 1984; 10: 160-203
- Information-processing abnormalities as neuropsychological vulnerability indicators for schizophrenia.Acta Psychiatr Scand. 1994; 90: 71-79
- Is it possible to be schizophrenic yet neuropsychologically normal?.Neuropsychology. 1997; 11: 437-446
- UCSD performance-based skills assessment.Schizophr Bull. 2001; 27: 235-245
- Information-processing deficits and thought disorder in schizophrenia.Am J Psychiatry. 1994; 151: 363-367
- Implications of a neural basis for social cognition for the study of schizophrenia.Am J Psychiatry. 2003; 160: 815-824
- Affective judgments of faces modulate early activity (approximately 160 ms) within the fusiform gyri.Neuroimage. 2002; 16: 663-677
- Neuropsychological function in schizophrenia.Arch Gen Psychiatry. 1991; 48: 618-624
- Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.Arch Gen Psychiatry. 1994; 51: 124-131
- A cognitive neuroscience view of schizophrenic thought disorder.Schizophr Bull. 1997; 23: 29-50
- Glucose effects on cognition in schizophrenia.Schizophr Res. 2003; 62: 93-9103
- The effect of tandospirone, a serotonin 1A agonist, on memory function in schizophrenia.Biol Psychiatry. 2001; 49: 861-868
- D-serine added to antipsychotics for the treatment of schizophrenia.Biol Psychiatry. 1998; 44: 1081-1089
- The joint WAIS-III and WMS-III factor structure.Psychol Assess. 2003; 15: 149-162
- Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence.Arch Gen Psychiatry. 1998; 55: 41-46
- Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease.Arch Neurol. 1992; 49: 448-452
- Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge.J Neurosci. 1998; 18: 411-418
- On the nature and pattern of neurocognitive function in major depressive disorder.Neuropsychiatry Neuropsychol Behav Neurol. 1998; 11: 111-119
Article info
Publication history
Accepted:
June 16,
2004
Received in revised form:
April 27,
2004
Received:
February 2,
2004
Identification
Copyright
© 2004 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
